nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—Methotrexate—colon cancer	0.324	1	CrCtD
Pralatrexate—TYMS—colon cancer	0.183	1	CbGaD
Pralatrexate—SLC19A1—Methotrexate—colon cancer	0.0675	0.278	CbGbCtD
Pralatrexate—TYMS—Capecitabine—colon cancer	0.0528	0.218	CbGbCtD
Pralatrexate—FPGS—Methotrexate—colon cancer	0.0488	0.201	CbGbCtD
Pralatrexate—Folic Acid—Methotrexate—colon cancer	0.0429	0.2	CrCrCtD
Pralatrexate—Tetrahydrofolic acid—Methotrexate—colon cancer	0.0429	0.2	CrCrCtD
Pralatrexate—Leucovorin—Methotrexate—colon cancer	0.0429	0.2	CrCrCtD
Pralatrexate—Pemetrexed—Methotrexate—colon cancer	0.0429	0.2	CrCrCtD
Pralatrexate—Raltitrexed—Methotrexate—colon cancer	0.0429	0.2	CrCrCtD
Pralatrexate—TYMS—Fluorouracil—colon cancer	0.0313	0.129	CbGbCtD
Pralatrexate—DHFR—Methotrexate—colon cancer	0.0248	0.102	CbGbCtD
Pralatrexate—TYMS—Methotrexate—colon cancer	0.0173	0.0712	CbGbCtD
Pralatrexate—Tumour lysis syndrome—Vincristine—colon cancer	0.000995	0.0712	CcSEcCtD
Pralatrexate—Tumour lysis syndrome—Irinotecan—colon cancer	0.000969	0.0694	CcSEcCtD
Pralatrexate—SLC19A1—lymphoid tissue—colon cancer	0.00086	0.0818	CbGeAlD
Pralatrexate—SLC19A1—digestive system—colon cancer	0.000849	0.0808	CbGeAlD
Pralatrexate—SLC19A1—liver—colon cancer	0.000633	0.0602	CbGeAlD
Pralatrexate—DHFR—embryo—colon cancer	0.000592	0.0563	CbGeAlD
Pralatrexate—FPGS—Fluoropyrimidine Activity—TYMS—colon cancer	0.000581	0.0598	CbGpPWpGaD
Pralatrexate—FPGS—lymphoid tissue—colon cancer	0.000573	0.0545	CbGeAlD
Pralatrexate—Raltitrexed—TYMS—colon cancer	0.000567	0.359	CrCbGaD
Pralatrexate—FPGS—digestive system—colon cancer	0.000566	0.0538	CbGeAlD
Pralatrexate—FPGS—vagina—colon cancer	0.0005	0.0475	CbGeAlD
Pralatrexate—SLC19A1—lymph node—colon cancer	0.000485	0.0462	CbGeAlD
Pralatrexate—Tumour lysis syndrome—Methotrexate—colon cancer	0.000483	0.0346	CcSEcCtD
Pralatrexate—TYMS—smooth muscle tissue—colon cancer	0.00047	0.0447	CbGeAlD
Pralatrexate—DHFR—renal system—colon cancer	0.000448	0.0426	CbGeAlD
Pralatrexate—Leucovorin—TYMS—colon cancer	0.00043	0.272	CrCbGaD
Pralatrexate—TYMS—Vinorelbine—Vincristine—colon cancer	0.000426	0.593	CbGdCrCtD
Pralatrexate—FPGS—liver—colon cancer	0.000421	0.0401	CbGeAlD
Pralatrexate—DHFR—G1/S-Specific Transcription—TYMS—colon cancer	0.000413	0.0424	CbGpPWpGaD
Pralatrexate—TYMS—lymphoid tissue—colon cancer	0.000376	0.0357	CbGeAlD
Pralatrexate—DHFR—lymphoid tissue—colon cancer	0.000372	0.0354	CbGeAlD
Pralatrexate—TYMS—digestive system—colon cancer	0.000371	0.0353	CbGeAlD
Pralatrexate—DHFR—digestive system—colon cancer	0.000367	0.035	CbGeAlD
Pralatrexate—Pemetrexed—TYMS—colon cancer	0.000343	0.218	CrCbGaD
Pralatrexate—TYMS—bone marrow—colon cancer	0.000342	0.0326	CbGeAlD
Pralatrexate—DHFR—bone marrow—colon cancer	0.000339	0.0322	CbGeAlD
Pralatrexate—Night sweats—Capecitabine—colon cancer	0.000333	0.0239	CcSEcCtD
Pralatrexate—TYMS—vagina—colon cancer	0.000328	0.0312	CbGeAlD
Pralatrexate—DHFR—vagina—colon cancer	0.000324	0.0309	CbGeAlD
Pralatrexate—FPGS—lymph node—colon cancer	0.000323	0.0307	CbGeAlD
Pralatrexate—Neoplasm malignant—Irinotecan—colon cancer	0.000315	0.0225	CcSEcCtD
Pralatrexate—TYMS—Vinblastine—Vincristine—colon cancer	0.000293	0.407	CbGdCrCtD
Pralatrexate—DHFR—One Carbon Metabolism—TYMS—colon cancer	0.000277	0.0285	CbGpPWpGaD
Pralatrexate—TYMS—liver—colon cancer	0.000276	0.0263	CbGeAlD
Pralatrexate—DHFR—liver—colon cancer	0.000274	0.026	CbGeAlD
Pralatrexate—Pharyngolaryngeal pain—Capecitabine—colon cancer	0.000267	0.0191	CcSEcCtD
Pralatrexate—Laryngeal pain—Capecitabine—colon cancer	0.000264	0.0189	CcSEcCtD
Pralatrexate—DHFR—Trans-sulfuration and one carbon metabolism—TYMS—colon cancer	0.000249	0.0256	CbGpPWpGaD
Pralatrexate—DHFR—Fluoropyrimidine Activity—TYMS—colon cancer	0.000243	0.025	CbGpPWpGaD
Pralatrexate—DHFR—E2F mediated regulation of DNA replication—TYMS—colon cancer	0.000243	0.025	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MSH6—colon cancer	0.000235	0.0241	CbGpPWpGaD
Pralatrexate—Sepsis—Irinotecan—colon cancer	0.000233	0.0167	CcSEcCtD
Pralatrexate—Sepsis—Fluorouracil—colon cancer	0.000224	0.016	CcSEcCtD
Pralatrexate—TYMS—lymph node—colon cancer	0.000212	0.0202	CbGeAlD
Pralatrexate—DHFR—lymph node—colon cancer	0.00021	0.02	CbGeAlD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MSH6—colon cancer	0.000205	0.021	CbGpPWpGaD
Pralatrexate—Pain in extremity—Vincristine—colon cancer	0.0002	0.0143	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—CA7—colon cancer	0.000198	0.0204	CbGpPWpGaD
Pralatrexate—FPGS—Fluoropyrimidine Activity—TP53—colon cancer	0.000193	0.0198	CbGpPWpGaD
Pralatrexate—Methotrexate—TYMS—colon cancer	0.000189	0.12	CrCbGaD
Pralatrexate—Dehydration—Vincristine—colon cancer	0.000186	0.0133	CcSEcCtD
Pralatrexate—Dehydration—Irinotecan—colon cancer	0.000182	0.013	CcSEcCtD
Pralatrexate—Hypokalaemia—Irinotecan—colon cancer	0.000178	0.0127	CcSEcCtD
Pralatrexate—SLC19A1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—colon cancer	0.000175	0.018	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—CA7—colon cancer	0.000169	0.0173	CbGpPWpGaD
Pralatrexate—Pancytopenia—Vincristine—colon cancer	0.000165	0.0118	CcSEcCtD
Pralatrexate—Neutropenia—Vincristine—colon cancer	0.000162	0.0116	CcSEcCtD
Pralatrexate—Neutropenia—Irinotecan—colon cancer	0.000158	0.0113	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Irinotecan—colon cancer	0.000157	0.0112	CcSEcCtD
Pralatrexate—Sepsis—Capecitabine—colon cancer	0.000156	0.0112	CcSEcCtD
Pralatrexate—Pancytopenia—Fluorouracil—colon cancer	0.000153	0.011	CcSEcCtD
Pralatrexate—DHFR—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—AKT1—colon cancer	0.000153	0.0157	CbGpPWpGaD
Pralatrexate—Upper respiratory tract infection—Fluorouracil—colon cancer	0.00015	0.0108	CcSEcCtD
Pralatrexate—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—colon cancer	0.000149	0.0153	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.000148	0.0152	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—LGR5—colon cancer	0.000144	0.0148	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CHST5—colon cancer	0.000144	0.0148	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TOP1—colon cancer	0.000142	0.0146	CbGpPWpGaD
Pralatrexate—Epistaxis—Fluorouracil—colon cancer	0.000136	0.00973	CcSEcCtD
Pralatrexate—Pain in extremity—Capecitabine—colon cancer	0.000131	0.00935	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—TP53—colon cancer	0.00013	0.0134	CbGpPWpGaD
Pralatrexate—DHFR—E2F transcription factor network—TYMS—colon cancer	0.000129	0.0132	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CHST5—colon cancer	0.000122	0.0125	CbGpPWpGaD
Pralatrexate—FPGS—Disease—LGR5—colon cancer	0.000122	0.0125	CbGpPWpGaD
Pralatrexate—Dehydration—Capecitabine—colon cancer	0.000122	0.0087	CcSEcCtD
Pralatrexate—Liver function test abnormal—Capecitabine—colon cancer	0.000121	0.00863	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—CHST5—colon cancer	0.00012	0.0124	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ODC1—colon cancer	0.00012	0.0124	CbGpPWpGaD
Pralatrexate—Hypokalaemia—Capecitabine—colon cancer	0.000119	0.00851	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.000118	0.00842	CcSEcCtD
Pralatrexate—Back pain—Vincristine—colon cancer	0.000117	0.00836	CcSEcCtD
Pralatrexate—Sepsis—Methotrexate—colon cancer	0.000116	0.00832	CcSEcCtD
Pralatrexate—Back pain—Irinotecan—colon cancer	0.000114	0.00814	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TYMS—colon cancer	0.000112	0.0115	CbGpPWpGaD
Pralatrexate—Anaemia—Vincristine—colon cancer	0.000112	0.00799	CcSEcCtD
Pralatrexate—Anaemia—Irinotecan—colon cancer	0.000109	0.00778	CcSEcCtD
Pralatrexate—Leukopenia—Vincristine—colon cancer	0.000108	0.00773	CcSEcCtD
Pralatrexate—Pancytopenia—Capecitabine—colon cancer	0.000107	0.00768	CcSEcCtD
Pralatrexate—DHFR—Metabolism of nitric oxide—AKT1—colon cancer	0.000106	0.0109	CbGpPWpGaD
Pralatrexate—Neutropenia—Capecitabine—colon cancer	0.000106	0.00756	CcSEcCtD
Pralatrexate—Leukopenia—Irinotecan—colon cancer	0.000105	0.00753	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Capecitabine—colon cancer	0.000105	0.00751	CcSEcCtD
Pralatrexate—Anaemia—Fluorouracil—colon cancer	0.000104	0.00745	CcSEcCtD
Pralatrexate—SLC19A1—Disease—AXIN2—colon cancer	0.000103	0.0106	CbGpPWpGaD
Pralatrexate—Cough—Irinotecan—colon cancer	0.000103	0.00734	CcSEcCtD
Pralatrexate—FPGS—Metabolism—CHST5—colon cancer	0.000102	0.0105	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ODC1—colon cancer	0.000102	0.0105	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.000101	0.0104	CbGpPWpGaD
Pralatrexate—Leukopenia—Fluorouracil—colon cancer	0.000101	0.00721	CcSEcCtD
Pralatrexate—Oedema—Vincristine—colon cancer	9.85e-05	0.00705	CcSEcCtD
Pralatrexate—Thrombocytopenia—Vincristine—colon cancer	9.65e-05	0.0069	CcSEcCtD
Pralatrexate—Oedema—Irinotecan—colon cancer	9.59e-05	0.00687	CcSEcCtD
Pralatrexate—Epistaxis—Capecitabine—colon cancer	9.5e-05	0.0068	CcSEcCtD
Pralatrexate—Thrombocytopenia—Irinotecan—colon cancer	9.39e-05	0.00672	CcSEcCtD
Pralatrexate—Anorexia—Vincristine—colon cancer	9.39e-05	0.00672	CcSEcCtD
Pralatrexate—DHFR—G1/S Transition—TYMS—colon cancer	9.34e-05	0.0096	CbGpPWpGaD
Pralatrexate—Oedema—Fluorouracil—colon cancer	9.19e-05	0.00658	CcSEcCtD
Pralatrexate—Anorexia—Irinotecan—colon cancer	9.15e-05	0.00655	CcSEcCtD
Pralatrexate—Thrombocytopenia—Fluorouracil—colon cancer	9e-05	0.00644	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—MLH3—colon cancer	8.99e-05	0.00924	CbGpPWpGaD
Pralatrexate—Liver function test abnormal—Methotrexate—colon cancer	8.98e-05	0.00643	CcSEcCtD
Pralatrexate—Tachycardia—Fluorouracil—colon cancer	8.97e-05	0.00642	CcSEcCtD
Pralatrexate—FPGS—Disease—AXIN2—colon cancer	8.77e-05	0.00902	CbGpPWpGaD
Pralatrexate—Anorexia—Fluorouracil—colon cancer	8.76e-05	0.00627	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Methotrexate—colon cancer	8.76e-05	0.00627	CcSEcCtD
Pralatrexate—Decreased appetite—Vincristine—colon cancer	8.56e-05	0.00613	CcSEcCtD
Pralatrexate—Dyspnoea—Irinotecan—colon cancer	8.55e-05	0.00612	CcSEcCtD
Pralatrexate—Fatigue—Vincristine—colon cancer	8.49e-05	0.00608	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	8.48e-05	0.00872	CbGpPWpGaD
Pralatrexate—Constipation—Vincristine—colon cancer	8.42e-05	0.00603	CcSEcCtD
Pralatrexate—Decreased appetite—Irinotecan—colon cancer	8.34e-05	0.00597	CcSEcCtD
Pralatrexate—Fatigue—Irinotecan—colon cancer	8.27e-05	0.00592	CcSEcCtD
Pralatrexate—Constipation—Irinotecan—colon cancer	8.2e-05	0.00587	CcSEcCtD
Pralatrexate—Dyspnoea—Fluorouracil—colon cancer	8.19e-05	0.00586	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Vincristine—colon cancer	8.06e-05	0.00577	CcSEcCtD
Pralatrexate—DHFR—Fluoropyrimidine Activity—TP53—colon cancer	8.05e-05	0.00828	CbGpPWpGaD
Pralatrexate—Decreased appetite—Fluorouracil—colon cancer	7.99e-05	0.00572	CcSEcCtD
Pralatrexate—Pancytopenia—Methotrexate—colon cancer	7.98e-05	0.00571	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—TYMS—colon cancer	7.87e-05	0.00809	CbGpPWpGaD
Pralatrexate—Neutropenia—Methotrexate—colon cancer	7.86e-05	0.00563	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Irinotecan—colon cancer	7.85e-05	0.00562	CcSEcCtD
Pralatrexate—TYMS—Cell Cycle—MLH3—colon cancer	7.84e-05	0.00806	CbGpPWpGaD
Pralatrexate—Upper respiratory tract infection—Methotrexate—colon cancer	7.81e-05	0.00559	CcSEcCtD
Pralatrexate—Abdominal pain—Vincristine—colon cancer	7.79e-05	0.00557	CcSEcCtD
Pralatrexate—Body temperature increased—Vincristine—colon cancer	7.79e-05	0.00557	CcSEcCtD
Pralatrexate—Back pain—Capecitabine—colon cancer	7.61e-05	0.00545	CcSEcCtD
Pralatrexate—Body temperature increased—Irinotecan—colon cancer	7.58e-05	0.00543	CcSEcCtD
Pralatrexate—Abdominal pain—Irinotecan—colon cancer	7.58e-05	0.00543	CcSEcCtD
Pralatrexate—Anaemia—Capecitabine—colon cancer	7.27e-05	0.00521	CcSEcCtD
Pralatrexate—Body temperature increased—Fluorouracil—colon cancer	7.26e-05	0.0052	CcSEcCtD
Pralatrexate—Epistaxis—Methotrexate—colon cancer	7.07e-05	0.00506	CcSEcCtD
Pralatrexate—Asthenia—Vincristine—colon cancer	7.07e-05	0.00506	CcSEcCtD
Pralatrexate—DHFR—Metabolism—CA7—colon cancer	7.05e-05	0.00725	CbGpPWpGaD
Pralatrexate—Leukopenia—Capecitabine—colon cancer	7.04e-05	0.00504	CcSEcCtD
Pralatrexate—TYMS—Fluoropyrimidine Activity—TP53—colon cancer	7.03e-05	0.00722	CbGpPWpGaD
Pralatrexate—Asthenia—Irinotecan—colon cancer	6.88e-05	0.00493	CcSEcCtD
Pralatrexate—Cough—Capecitabine—colon cancer	6.87e-05	0.00491	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	6.78e-05	0.00697	CbGpPWpGaD
Pralatrexate—Diarrhoea—Vincristine—colon cancer	6.74e-05	0.00483	CcSEcCtD
Pralatrexate—Diarrhoea—Irinotecan—colon cancer	6.56e-05	0.0047	CcSEcCtD
Pralatrexate—Pruritus—Fluorouracil—colon cancer	6.5e-05	0.00465	CcSEcCtD
Pralatrexate—Oedema—Capecitabine—colon cancer	6.42e-05	0.0046	CcSEcCtD
Pralatrexate—Diarrhoea—Fluorouracil—colon cancer	6.29e-05	0.0045	CcSEcCtD
Pralatrexate—Thrombocytopenia—Capecitabine—colon cancer	6.29e-05	0.0045	CcSEcCtD
Pralatrexate—Tachycardia—Capecitabine—colon cancer	6.27e-05	0.00449	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—CDKN1A—colon cancer	6.27e-05	0.00644	CbGpPWpGaD
Pralatrexate—Vomiting—Vincristine—colon cancer	6.26e-05	0.00448	CcSEcCtD
Pralatrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—colon cancer	6.23e-05	0.0064	CbGpPWpGaD
Pralatrexate—Rash—Vincristine—colon cancer	6.21e-05	0.00445	CcSEcCtD
Pralatrexate—Dermatitis—Vincristine—colon cancer	6.21e-05	0.00444	CcSEcCtD
Pralatrexate—TYMS—Metabolism—CA7—colon cancer	6.15e-05	0.00632	CbGpPWpGaD
Pralatrexate—Anorexia—Capecitabine—colon cancer	6.12e-05	0.00438	CcSEcCtD
Pralatrexate—Vomiting—Irinotecan—colon cancer	6.1e-05	0.00437	CcSEcCtD
Pralatrexate—Rash—Irinotecan—colon cancer	6.05e-05	0.00433	CcSEcCtD
Pralatrexate—Dermatitis—Irinotecan—colon cancer	6.04e-05	0.00433	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—EP300—colon cancer	5.96e-05	0.00613	CbGpPWpGaD
Pralatrexate—Nausea—Vincristine—colon cancer	5.85e-05	0.00419	CcSEcCtD
Pralatrexate—Vomiting—Fluorouracil—colon cancer	5.84e-05	0.00418	CcSEcCtD
Pralatrexate—Rash—Fluorouracil—colon cancer	5.79e-05	0.00415	CcSEcCtD
Pralatrexate—Dermatitis—Fluorouracil—colon cancer	5.79e-05	0.00414	CcSEcCtD
Pralatrexate—Dyspnoea—Capecitabine—colon cancer	5.72e-05	0.0041	CcSEcCtD
Pralatrexate—Nausea—Irinotecan—colon cancer	5.7e-05	0.00408	CcSEcCtD
Pralatrexate—Back pain—Methotrexate—colon cancer	5.67e-05	0.00406	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	5.63e-05	0.00579	CbGpPWpGaD
Pralatrexate—Decreased appetite—Capecitabine—colon cancer	5.58e-05	0.004	CcSEcCtD
Pralatrexate—Fatigue—Capecitabine—colon cancer	5.54e-05	0.00396	CcSEcCtD
Pralatrexate—Constipation—Capecitabine—colon cancer	5.49e-05	0.00393	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—CDKN1A—colon cancer	5.47e-05	0.00562	CbGpPWpGaD
Pralatrexate—Nausea—Fluorouracil—colon cancer	5.46e-05	0.00391	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	5.45e-05	0.0056	CbGpPWpGaD
Pralatrexate—Anaemia—Methotrexate—colon cancer	5.41e-05	0.00388	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	5.3e-05	0.00544	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Capecitabine—colon cancer	5.25e-05	0.00376	CcSEcCtD
Pralatrexate—Leukopenia—Methotrexate—colon cancer	5.24e-05	0.00375	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—EP300—colon cancer	5.2e-05	0.00535	CbGpPWpGaD
Pralatrexate—DHFR—E2F transcription factor network—MYC—colon cancer	5.2e-05	0.00534	CbGpPWpGaD
Pralatrexate—Cough—Methotrexate—colon cancer	5.11e-05	0.00366	CcSEcCtD
Pralatrexate—DHFR—Disease—LGR5—colon cancer	5.1e-05	0.00524	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CHST5—colon cancer	5.1e-05	0.00524	CbGpPWpGaD
Pralatrexate—Body temperature increased—Capecitabine—colon cancer	5.08e-05	0.00363	CcSEcCtD
Pralatrexate—Abdominal pain—Capecitabine—colon cancer	5.08e-05	0.00363	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	5.01e-05	0.00515	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	4.91e-05	0.00505	CbGpPWpGaD
Pralatrexate—Methotrexate—ABCB1—colon cancer	4.8e-05	0.0304	CrCbGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	4.75e-05	0.00488	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Methotrexate—colon cancer	4.68e-05	0.00335	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—TP53—colon cancer	4.63e-05	0.00475	CbGpPWpGaD
Pralatrexate—Asthenia—Capecitabine—colon cancer	4.61e-05	0.0033	CcSEcCtD
Pralatrexate—Anorexia—Methotrexate—colon cancer	4.56e-05	0.00326	CcSEcCtD
Pralatrexate—DHFR—G1/S Transition—CDKN1A—colon cancer	4.55e-05	0.00467	CbGpPWpGaD
Pralatrexate—Pruritus—Capecitabine—colon cancer	4.54e-05	0.00325	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—MYC—colon cancer	4.53e-05	0.00466	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—colon cancer	4.52e-05	0.00464	CbGpPWpGaD
Pralatrexate—Diarrhoea—Capecitabine—colon cancer	4.39e-05	0.00315	CcSEcCtD
Pralatrexate—DHFR—Metabolism—ODC1—colon cancer	4.27e-05	0.00439	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—CHST5—colon cancer	4.27e-05	0.00439	CbGpPWpGaD
Pralatrexate—Dyspnoea—Methotrexate—colon cancer	4.26e-05	0.00305	CcSEcCtD
Pralatrexate—Decreased appetite—Methotrexate—colon cancer	4.16e-05	0.00297	CcSEcCtD
Pralatrexate—Fatigue—Methotrexate—colon cancer	4.12e-05	0.00295	CcSEcCtD
Pralatrexate—Vomiting—Capecitabine—colon cancer	4.08e-05	0.00292	CcSEcCtD
Pralatrexate—Rash—Capecitabine—colon cancer	4.05e-05	0.0029	CcSEcCtD
Pralatrexate—Dermatitis—Capecitabine—colon cancer	4.05e-05	0.0029	CcSEcCtD
Pralatrexate—TYMS—G1/S Transition—CDKN1A—colon cancer	3.97e-05	0.00408	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CCND1—colon cancer	3.96e-05	0.00407	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MLH1—colon cancer	3.96e-05	0.00407	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MYC—colon cancer	3.94e-05	0.00405	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Methotrexate—colon cancer	3.91e-05	0.0028	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN1A—colon cancer	3.83e-05	0.00394	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—APC—colon cancer	3.82e-05	0.00392	CbGpPWpGaD
Pralatrexate—Nausea—Capecitabine—colon cancer	3.81e-05	0.00273	CcSEcCtD
Pralatrexate—Body temperature increased—Methotrexate—colon cancer	3.78e-05	0.00271	CcSEcCtD
Pralatrexate—Abdominal pain—Methotrexate—colon cancer	3.78e-05	0.00271	CcSEcCtD
Pralatrexate—DHFR—G1/S Transition—MYC—colon cancer	3.77e-05	0.00388	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—BUB1B—colon cancer	3.76e-05	0.00387	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—CHST5—colon cancer	3.73e-05	0.00383	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ODC1—colon cancer	3.73e-05	0.00383	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—colon cancer	3.71e-05	0.00381	CbGpPWpGaD
Pralatrexate—DHFR—Disease—AXIN2—colon cancer	3.66e-05	0.00377	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—PPARG—colon cancer	3.54e-05	0.00364	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CCND1—colon cancer	3.46e-05	0.00355	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MLH1—colon cancer	3.45e-05	0.00355	CbGpPWpGaD
Pralatrexate—Asthenia—Methotrexate—colon cancer	3.43e-05	0.00246	CcSEcCtD
Pralatrexate—Pruritus—Methotrexate—colon cancer	3.38e-05	0.00242	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle—BUB1B—colon cancer	3.36e-05	0.00346	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN1A—colon cancer	3.34e-05	0.00344	CbGpPWpGaD
Pralatrexate—TYMS—G1/S Transition—MYC—colon cancer	3.29e-05	0.00338	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—BUB1B—colon cancer	3.28e-05	0.00338	CbGpPWpGaD
Pralatrexate—Diarrhoea—Methotrexate—colon cancer	3.27e-05	0.00234	CcSEcCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—colon cancer	3.24e-05	0.00333	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ABCB1—colon cancer	3.18e-05	0.00327	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—MYC—colon cancer	3.18e-05	0.00327	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—TYMS—colon cancer	3.12e-05	0.00321	CbGpPWpGaD
Pralatrexate—Vomiting—Methotrexate—colon cancer	3.04e-05	0.00218	CcSEcCtD
Pralatrexate—Rash—Methotrexate—colon cancer	3.01e-05	0.00216	CcSEcCtD
Pralatrexate—Dermatitis—Methotrexate—colon cancer	3.01e-05	0.00216	CcSEcCtD
Pralatrexate—SLC19A1—Disease—FGFR3—colon cancer	2.98e-05	0.00306	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—BUB1B—colon cancer	2.94e-05	0.00302	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.9e-05	0.00298	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—TYMS—colon cancer	2.89e-05	0.00297	CbGpPWpGaD
Pralatrexate—Nausea—Methotrexate—colon cancer	2.84e-05	0.00203	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—MYC—colon cancer	2.77e-05	0.00285	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—APC—colon cancer	2.73e-05	0.00281	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ABCB1—colon cancer	2.7e-05	0.00278	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	2.69e-05	0.00277	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—TYMS—colon cancer	2.65e-05	0.00273	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	2.62e-05	0.00269	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	2.59e-05	0.00267	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TYMS—colon cancer	2.58e-05	0.00265	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—BRAF—colon cancer	2.57e-05	0.00264	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	2.53e-05	0.0026	CbGpPWpGaD
Pralatrexate—FPGS—Disease—FGFR3—colon cancer	2.53e-05	0.0026	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	2.41e-05	0.00248	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	2.34e-05	0.00241	CbGpPWpGaD
Pralatrexate—FPGS—Disease—APC—colon cancer	2.33e-05	0.00239	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—EP300—colon cancer	2.31e-05	0.00238	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	2.28e-05	0.00235	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PPARG—colon cancer	2.21e-05	0.00227	CbGpPWpGaD
Pralatrexate—FPGS—Disease—BRAF—colon cancer	2.19e-05	0.00225	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	2.1e-05	0.00216	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	2.1e-05	0.00215	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTGS2—colon cancer	2.08e-05	0.00213	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	2.05e-05	0.00211	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.94e-05	0.002	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PPARG—colon cancer	1.88e-05	0.00193	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CTNNB1—colon cancer	1.86e-05	0.00191	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—CDKN1A—colon cancer	1.81e-05	0.00187	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.78e-05	0.00183	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTGS2—colon cancer	1.77e-05	0.00181	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PTGS2—colon cancer	1.74e-05	0.00179	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EP300—colon cancer	1.73e-05	0.00178	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.72e-05	0.00177	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—SRC—colon cancer	1.68e-05	0.00173	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—colon cancer	1.66e-05	0.0017	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—NRAS—colon cancer	1.62e-05	0.00166	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CTNNB1—colon cancer	1.58e-05	0.00162	CbGpPWpGaD
Pralatrexate—FPGS—Disease—CDKN1A—colon cancer	1.54e-05	0.00159	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MYC—colon cancer	1.5e-05	0.00155	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—TGFB1—colon cancer	1.5e-05	0.00154	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PTGS2—colon cancer	1.48e-05	0.00152	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—EGFR—colon cancer	1.47e-05	0.00151	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EP300—colon cancer	1.47e-05	0.00151	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.46e-05	0.0015	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CCND1—colon cancer	1.45e-05	0.00149	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—EP300—colon cancer	1.45e-05	0.00149	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SRC—colon cancer	1.43e-05	0.00147	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN1A—colon cancer	1.41e-05	0.00144	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—KRAS—colon cancer	1.39e-05	0.00143	CbGpPWpGaD
Pralatrexate—FPGS—Disease—NRAS—colon cancer	1.37e-05	0.00141	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—EP300—colon cancer	1.34e-05	0.00137	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CCND1—colon cancer	1.3e-05	0.00134	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MYC—colon cancer	1.28e-05	0.00132	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PIK3CA—colon cancer	1.28e-05	0.00131	CbGpPWpGaD
Pralatrexate—FPGS—Disease—TGFB1—colon cancer	1.28e-05	0.00131	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CCND1—colon cancer	1.27e-05	0.0013	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN1A—colon cancer	1.26e-05	0.00129	CbGpPWpGaD
Pralatrexate—FPGS—Disease—EGFR—colon cancer	1.25e-05	0.00129	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—EP300—colon cancer	1.23e-05	0.00126	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN1A—colon cancer	1.23e-05	0.00126	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—EP300—colon cancer	1.2e-05	0.00123	CbGpPWpGaD
Pralatrexate—FPGS—Disease—KRAS—colon cancer	1.18e-05	0.00122	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HRAS—colon cancer	1.18e-05	0.00121	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—EP300—colon cancer	1.17e-05	0.0012	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MYC—colon cancer	1.17e-05	0.0012	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CCND1—colon cancer	1.13e-05	0.00117	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ABCB1—colon cancer	1.13e-05	0.00116	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—TYMS—colon cancer	1.11e-05	0.00114	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN1A—colon cancer	1.1e-05	0.00113	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PIK3CA—colon cancer	1.09e-05	0.00112	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—PIK3CA—colon cancer	1.07e-05	0.0011	CbGpPWpGaD
Pralatrexate—DHFR—Disease—FGFR3—colon cancer	1.06e-05	0.00109	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—AKT1—colon cancer	1.04e-05	0.00107	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—EP300—colon cancer	1.04e-05	0.00107	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MYC—colon cancer	1.04e-05	0.00107	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MYC—colon cancer	1.02e-05	0.00105	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HRAS—colon cancer	1e-05	0.00103	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ABCB1—colon cancer	9.85e-06	0.00101	CbGpPWpGaD
Pralatrexate—DHFR—Disease—APC—colon cancer	9.71e-06	0.000999	CbGpPWpGaD
Pralatrexate—DHFR—Disease—BRAF—colon cancer	9.13e-06	0.000939	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PIK3CA—colon cancer	9.1e-06	0.000935	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MYC—colon cancer	9.09e-06	0.000935	CbGpPWpGaD
Pralatrexate—FPGS—Disease—AKT1—colon cancer	8.87e-06	0.000912	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—AKT1—colon cancer	8.74e-06	0.000898	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—colon cancer	8.56e-06	0.00088	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PPARG—colon cancer	7.85e-06	0.000807	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—colon cancer	7.47e-06	0.000768	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—AKT1—colon cancer	7.43e-06	0.000764	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTGS2—colon cancer	7.38e-06	0.000758	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PPARG—colon cancer	6.85e-06	0.000704	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CTNNB1—colon cancer	6.6e-06	0.000678	CbGpPWpGaD
Pralatrexate—DHFR—Disease—CDKN1A—colon cancer	6.45e-06	0.000663	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PTGS2—colon cancer	6.18e-06	0.000635	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EP300—colon cancer	6.13e-06	0.000631	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SRC—colon cancer	5.96e-06	0.000613	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NRAS—colon cancer	5.74e-06	0.00059	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PTGS2—colon cancer	5.39e-06	0.000554	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MYC—colon cancer	5.35e-06	0.000549	CbGpPWpGaD
Pralatrexate—DHFR—Disease—TGFB1—colon cancer	5.33e-06	0.000548	CbGpPWpGaD
Pralatrexate—DHFR—Disease—EGFR—colon cancer	5.23e-06	0.000537	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—EP300—colon cancer	5.14e-06	0.000528	CbGpPWpGaD
Pralatrexate—DHFR—Disease—KRAS—colon cancer	4.94e-06	0.000508	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PIK3CA—colon cancer	4.54e-06	0.000466	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—EP300—colon cancer	4.48e-06	0.000461	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HRAS—colon cancer	4.2e-06	0.000432	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—PIK3CA—colon cancer	3.8e-06	0.000391	CbGpPWpGaD
Pralatrexate—DHFR—Disease—AKT1—colon cancer	3.71e-06	0.000381	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PIK3CA—colon cancer	3.32e-06	0.000341	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—AKT1—colon cancer	3.1e-06	0.000319	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—AKT1—colon cancer	2.71e-06	0.000278	CbGpPWpGaD
